Company Profile
NGM Biopharmaceuticals Stock Price, News & Analysis
- Ticker:
- NGM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for NGM.
Company overview
Business overview
NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs. Its business has been shaped by a broad platform approach and ongoing portfolio decisions.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, NGM sits in specialty biotechnology.
Business Model Characteristics
The company depends on pipeline prioritization, clinical data, and the ability to create value from a broad discovery engine.
Position Within the Biotechnology Landscape
NGM is a platform biotech name whose valuation depends on the quality of its selected programs.
Future catalysts
NGM is now largely a legacy and strategic-closeout story, so the catalysts are any asset monetization, wind-down, or portfolio-simplification update. The market is mainly waiting for clarity on the remaining corporate value.
Recent news
- 01
- 02
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
Source: NGM Biopharmaceuticals
- 03
- 04
- 05
NGM Bio Announces Closing of Tender Offer
Source: NGM Biopharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does NGM Biopharmaceuticals do?
NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs. Its business has been shaped by a broad platform approach and ongoing portfolio decisions.
On which exchange is NGM stock listed?
NGM Biopharmaceuticals (NGM) is associated with NASDAQ, United States, Biopharma.
What is Biopharmaceuticals?
NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs.
Which conditions is NGM Biopharmaceuticals targeting with Biopharmaceuticals?
NGM Biopharmaceuticals is associated with oncology, metabolic disease based on its company overview and current catalyst commentary.
How does NGM Biopharmaceuticals describe recent progress with Biopharmaceuticals?
NGM is now largely a legacy and strategic-closeout story, so the catalysts are any asset monetization, wind-down, or portfolio-simplification update. The market is mainly waiting for clarity on the remaining corporate value.
What future catalysts are investors watching for NGM Biopharmaceuticals?
NGM is now largely a legacy and strategic-closeout story, so the catalysts are any asset monetization, wind-down, or portfolio-simplification update. The market is mainly waiting for clarity on the remaining corporate value.